{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:35:35Z","timestamp":1790807735704,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"The university hospital of Nantes"},{"name":"French Ministry of Health"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clineu-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.clineuro.2016.04.021","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T21:22:19Z","timestamp":1461964939000},"page":"35-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy"],"prefix":"10.1016","volume":"146","author":[{"given":"Laur\u00e8ne","family":"Leclair-Visonneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiphaine","family":"Rouaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9rang\u00e8re","family":"Debilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Durif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Houeto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Kreisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Defebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Volteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine Le","family":"Dily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Damier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Boutoleau-Bretonni\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Lejeune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Derkinderen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2016.04.021_bib0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/archneur.1964.00460160003001","article-title":"Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia","volume":"10","author":"Steele","year":"1964","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.clineuro.2016.04.021_bib0010","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1136\/jnnp.60.6.615","article-title":"Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study","volume":"60","author":"Litvan","year":"1996","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2016.04.021_bib0015","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1212\/WNL.44.11.2015","article-title":"Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy)","volume":"44","author":"Hauw","year":"1994","journal-title":"Neurology"},{"issue":"Suppl. 1","key":"10.1016\/j.clineuro.2016.04.021_bib0020","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.3233\/JAD-132054","article-title":"Intracellular and extracellular roles for tau in neurodegenerative disease","volume":"40","author":"Hanger","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.clineuro.2016.04.021_bib0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molbrainres.2003.11.007","article-title":"Differential involvement and heterogeneous phosphorylation of tau isoforms in progressive supranuclear palsy","volume":"121","author":"Gibb","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.clineuro.2016.04.021_bib0030","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.molmed.2009.01.003","article-title":"Tau phosphorylation: the therapeutic challenge for neurodegenerative disease","volume":"15","author":"Hanger","year":"2009","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.clineuro.2016.04.021_bib0035","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0896-6273(03)00259-9","article-title":"Cdk5 is a key factor in tau aggregation and tangle formation in vivo","volume":"38","author":"Noble","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.clineuro.2016.04.021_bib0040","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0014-5793(94)00702-0","article-title":"PHF-tau from Alzheimer's brain comprises four species on SDS-PAGE which can be mimicked by in vitro phosphorylation of human brain tau by glycogen synthase kinase-3 beta","volume":"349","author":"Mulot","year":"1994","journal-title":"FEBS Lett."},{"key":"10.1016\/j.clineuro.2016.04.021_bib0045","doi-asserted-by":"crossref","first-page":"42060","DOI":"10.1074\/jbc.M202241200","article-title":"Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells","volume":"277","author":"Sato","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clineuro.2016.04.021_bib0050","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0002-9440(10)63465-7","article-title":"Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice","volume":"163","author":"Ishizawa","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.clineuro.2016.04.021_bib0055","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1073\/pnas.0500466102","article-title":"Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo","volume":"102","author":"Noble","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clineuro.2016.04.021_bib0060","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00401-002-0587-8","article-title":"Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimers disease, Picks disease, progressive supranuclear palsy and corticobasal degeneration","volume":"104","author":"Ferrer","year":"2002","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.clineuro.2016.04.021_bib0065","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1046\/j.1471-4159.1999.720879.x","article-title":"The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS","volume":"72","author":"Chen","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.clineuro.2016.04.021_bib0070","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1212\/WNL.46.4.922","article-title":"Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)","volume":"46","author":"Litvan","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2016.04.021_bib0075","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/brain\/awm032","article-title":"A clinical rating scale for progressive supranuclear palsy","volume":"130","author":"Golbe","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.clineuro.2016.04.021_bib0080","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1242\/jcs.01018","article-title":"Role of tau phosphorylation by glycogen synthase kinase-3beta in the regulation of organelle transport","volume":"117","author":"Tatebayashi","year":"2004","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.clineuro.2016.04.021_bib0085","doi-asserted-by":"crossref","first-page":"9162","DOI":"10.1523\/JNEUROSCI.23-27-09162.2003","article-title":"Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis","volume":"23","author":"Dou","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.clineuro.2016.04.021_bib0090","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/mds.25824","article-title":"A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy","volume":"29","author":"Tolosa","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.clineuro.2016.04.021_bib0095","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","article-title":"Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial","volume":"13","author":"Boxer","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2016.04.021_bib0100","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/BF00310132","article-title":"Modified tau is present in younger nondemented persons: a study of subcortical nuclei in Alzheimer's disease and progressive supranuclear palsy","volume":"81","author":"Shin","year":"1991","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.clineuro.2016.04.021_bib0105","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1750-3639.2007.00054.x","article-title":"Progressive supranuclear palsy: pathology and genetics","volume":"17","author":"Dickson","year":"2007","journal-title":"Brain Pathol."},{"key":"10.1016\/j.clineuro.2016.04.021_bib0110","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.parkreldis.2011.02.017","article-title":"Neuropathological findings of PSP in the elderly without clinical PSP: possible incidental PSP?","volume":"17","author":"Evidente","year":"2011","journal-title":"Parkinsonism Relat. Dis."},{"key":"10.1016\/j.clineuro.2016.04.021_bib0115","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.clineuro.2016.04.021_bib0120","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1212\/WNL.0b013e318230a16c","article-title":"Chronic divalproex sodium use and brain atrophy in Alzheimer disease","volume":"77","author":"Fleisher","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2016.04.021_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2006.00655.x","article-title":"Valproate-induced hyperammonemic encephalopathy","volume":"114","author":"Segura-Bruna","year":"2006","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.clineuro.2016.04.021_bib0130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/mds.25065","article-title":"Biomarkers for trials of neuroprotection in Parkinson's disease","volume":"28","author":"Agarwal","year":"2013","journal-title":"Mov. Disord."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030384671630155X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030384671630155X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T07:57:46Z","timestamp":1600502266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030384671630155X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":26,"alternative-id":["S030384671630155X"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2016.04.021","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2016.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}